Clinical AI Intake and Triage in Viet Nam: A Practical Framework for Screening, Routing and Risk-Proportionate Review Before Procurement or Deployment
PRACTICAL FRAMEWORKS & TOOLS
Clinical AI Intake and Triage in Viet Nam: A Practical Framework for Screening, Routing and Risk-Proportionate Review Before Procurement or Deployment
PRACTICAL FRAMEWORKS & TOOLS
Last reviewed: 6 October 2026
Clinical AI does not always enter a healthcare organization through a formal “AI project.” It may arrive through a vendor proposal, a new module added to an existing hospital information system, an imaging device with embedded AI, a department requesting a pilot, an internally developed model, a research collaboration, a software renewal or staff beginning to use a general-purpose generative AI tool for healthcare work.
That creates a basic governance problem. If an organization only begins asking questions after procurement, contracting or technical integration has already started, important decisions may already have been made. The intended use may have been shaped by the vendor rather than the healthcare organization. Data may already be expected to flow to an external platform. A department may have promised a pilot. Clinical staff may assume that the system has been approved simply because IT or procurement is involved. Governance then becomes a retrospective effort to control a pathway that is already moving.
A better approach is to create a clear front door for AI. Clinical AI intake is that front door. Its purpose is not to conduct every legal, clinical, technical, privacy, cybersecurity and procurement review at once. It is to identify what is being proposed, understand enough about the intended use to recognize material concerns, determine what information or evidence is missing and route the request to an appropriate level of review before the organization becomes committed.
In this article, clinical AI intake includes AI proposed for clinical care, care support and care-relevant operations where its use may materially affect patients, healthcare professionals, clinical information, healthcare decisions or important workflows. That broader scope matters because AI can influence care even when the software itself is not marketed primarily as a clinical product.
This has become particularly timely internationally. On 1 October 2026, the Coalition for Health AI released its AI Intake Playbook and AI Intake Controls and Evidence Workbook. The draft framework contains 57 controls across 11 domains, developed from more than 800 questions drawn from approximately 16 questionnaires in use across participating health systems. Sixteen baseline controls apply to every vendor, with additional controls added according to the risk of the proposed deployment [7]. As of this review, these materials remain a draft framework entering pilot testing, not a finalized standard or regulatory requirement.
The importance of intake is broader than vendor efficiency. The same AI platform may support several very different use cases with very different consequences. A general-purpose model used to draft an internal administrative memo is not the same governance problem as the same model being used to generate discharge instructions or influence clinical decisions. Intake therefore needs to examine the proposed use of AI within the local healthcare system, not simply the name of the product.
For healthcare organizations in Viet Nam, the central question is straightforward: before an AI system enters procurement, pilot implementation or routine use, do we know enough to decide what review it actually needs?
AI intake is not the same as AI approval
An intake process should not become a miniature approval committee. At the intake stage, an organization will often not have enough information to make a complete judgment about clinical effectiveness, cybersecurity, legal compliance, privacy, local validation, human factors or contractual terms. Trying to resolve all of those issues through one initial form usually creates either an excessively burdensome questionnaire or a superficial review that gives false reassurance.
The intake function should answer narrower questions. What exactly is being proposed? What healthcare problem is it intended to address? Where will AI affect care or operations? Which patients, staff, data and workflows are involved? What could happen if it fails? Which specialists need to review it? What information or evidence must be obtained before a further decision can be made?
The output of intake may therefore be a route rather than an approval. One proposal may proceed through a streamlined organizational review. Another may require clinical-safety assessment and local validation. Another may need data-protection, cybersecurity, medical-device or legal review. A high-consequence use may require multidisciplinary governance review before procurement discussions continue, while an incomplete submission may simply be returned for further information.
Keeping intake and approval separate reduces two opposite risks: turning governance into an unnecessary bottleneck, or allowing a quick initial screen to become an unintended shortcut to deployment.
Organizational intake is not the same as statutory AI risk classification
This distinction is particularly important in Viet Nam. Law No. 134/2025/QH15 on Artificial Intelligence has been effective since 1 March 2026. Under Article 10, the AI provider is responsible for classifying the AI system before it is put into use. Medium-risk and high-risk systems require a classification dossier, and the provider must notify the classification result to the Ministry of Science and Technology through the AI one-stop electronic information portal before the system is put into use [1].
A deployer may rely on the provider's classification. However, if the deployer modifies, integrates or changes the system's functions in a way that creates a new or higher level of risk, it must coordinate with the provider to carry out reclassification [1]. Decree No. 142/2026/NĐ-CP, effective since 1 May 2026, further specifies the classification framework and the information expected in classification documentation for medium- and high-risk systems, including the system's intended use, deployment context, users and affected persons, principal input data and risk-management measures [2].
Decision No. 33/2026/QĐ-TTg, effective since 15 August 2026, separately establishes the current List of High-Risk Artificial Intelligence Systems [3].
An internal healthcare AI intake process should therefore not present itself as the statutory AI risk-classification mechanism. The two processes serve different purposes. Legal classification asks how the AI system is classified under Vietnamese law and what legal responsibilities follow. Organizational intake asks whether the proposed local use requires particular levels of clinical, quality, privacy, cybersecurity, procurement or governance scrutiny.
The two processes may inform one another, but they are not interchangeable. An AI system that is not legally classified as high-risk may still deserve intensive organizational review if its local use could materially affect diagnosis, treatment, patient communication, clinical workflow or continuity of care.
For that reason, healthcare organizations should also be cautious about using “low-risk,” “medium-risk” and “high-risk” as names for internal intake pathways. Those terms already have statutory significance. A clearer organizational approach is to use review pathways such as streamlined review, enhanced review and comprehensive review, which describe the depth of organizational scrutiny without implying a legal classification.
Intake should begin with the use case, not the product
One of the most common weaknesses in technology governance is asking “What does this product do?” before asking “What are we proposing to do with it?”
The distinction matters because the same AI-enabled platform may schedule appointments, summarize internal documents, draft patient messages, analyze images or support clinical decision-making. Product-level information can tell the organization something about the technology, but governance implications emerge from the combination of technology + intended use + users + patients + workflow + data + operating environment.
CHAI's new intake work reflects the same distinction. Its contributors describe AI evaluation as occurring at organizational, product and use-case levels, with use-case assessment being especially challenging because one platform can support several applications with different risk profiles [7].
The first meaningful intake field should therefore not simply be the vendor or model name. It should be a short, understandable description of the intended use. For example, “Use an AI-enabled system to prioritize chest radiographs for earlier radiologist review when specified abnormalities are suspected” is much more useful for governance than “Implement Vendor X AI platform.”
A good use-case statement should explain what problem is being addressed, what the AI contributes, who receives or uses the output and what decision or action may follow. If the requester cannot explain the intended use clearly, the organization may not yet be ready to evaluate the technology.
The first intake question may be whether AI is needed at all
AI governance should not begin from the assumption that an AI solution must be deployed. A department may request AI because a vendor demonstration was impressive, because another hospital is using similar technology or because an existing operational problem has become frustrating. Intake provides an opportunity to return to the underlying need.
What problem is the organization trying to solve? How is that problem currently measured? Is AI necessary? Could workflow redesign, staffing changes, conventional software, better integration or improved data quality solve it more effectively?
This is not an anti-innovation position. It prevents the organization from committing governance effort, procurement resources and clinical attention to technologies that do not address the real constraint. An effective intake process therefore begins with a problem statement, followed by the proposed AI use case. Technology should follow the healthcare need rather than define it.
Create one visible entry point
A governance process is difficult to use if staff do not know where it begins. Healthcare organizations should establish a recognizable route through which proposed AI use can enter review. Depending on organizational size, this could be an online intake form, a governance mailbox, a structured procurement request, a quality-management workflow or an existing technology-review process with an AI-specific component.
What matters is consistency. A clinician seeking to pilot an AI tool, an IT department considering a new module, a procurement team evaluating an AI-enabled product and a department receiving new AI functionality through a software update should not need completely different routes simply to determine whether governance review is required.
The entry point should also capture AI that does not arrive through conventional purchasing. Internally developed models, donated or free pilots, research-to-clinical transitions, externally hosted tools and substantial AI capabilities introduced through upgrades may all require governance attention even when no new procurement contract is being initiated.
A useful organizational principle is that if an AI capability may materially affect patient care, clinical information, healthcare decisions, sensitive data or important healthcare operations, there should be a visible route into governance.
The minimum intake package should be small enough to complete and strong enough to route
A common governance failure is asking every requester to complete an exhaustive assessment before the organization even knows whether detailed review is necessary. A better approach separates the minimum information needed for triage from the more extensive evidence required during subsequent assessment.
At minimum, the organization should understand what the AI is, what problem it is intended to address, its proposed use and boundaries, which department owns the request, who will use it, whether patients are directly affected, which decisions or workflow steps may change, what data are involved, whether information leaves the organization's environment, whether the system can act or communicate without immediate human approval, whether a vendor or statutory AI provider is involved, and whether the capability is already being used elsewhere in the organization.
The requester should also explain what happens after the AI produces an output, because this often reveals more about organizational and clinical risk than a long description of the model. If nothing happens until an analyst reviews the output for internal planning, the review pathway may be relatively limited. If the output reaches a clinician and may influence diagnosis or treatment, clinical-safety and evidence review become more important. If AI communicates directly with a patient or can trigger another system or action, the organization needs to examine autonomy, action authority, human oversight, escalation and fallback much more closely.
Intake should screen for consequences, not technical sophistication
A technically complex AI model is not necessarily the highest-consequence organizational use, and a comparatively simple model may create substantial harm if positioned at a critical point in care.
Triage should therefore focus on consequences. How close is the AI output to a clinical decision? Could an error cause patient harm? Would the effect be reversible? Is there a realistic opportunity for a person to detect the error before it affects care? Does AI communicate directly with patients? Can it initiate actions? Are vulnerable populations affected? Are sensitive data involved? How many patients or sites could be exposed? Can safe care continue if the technology becomes unavailable or unreliable?
Scale matters as well. A low-consequence capability used by three administrative employees is not the same organizational problem as the same functionality deployed across an entire hospital group. Uncertainty should also influence review depth. A novel use with weak or limited evidence may justify enhanced scrutiny even where the anticipated consequence appears moderate, because important failure modes may still be poorly understood.
Risk-proportionate intake is therefore not simply about asking “How dangerous is this algorithm?” The more useful question is “What could happen in this healthcare environment if this proposed use does not work as expected?”
A legal and regulatory screen should occur early, but it is not the whole intake process
AI intake should identify legal questions early enough that they do not first emerge after procurement. The initial screen should consider whether the proposed system may trigger obligations under Viet Nam's AI regulatory framework; whether medical-device regulation may apply; whether personal-data protection requirements are relevant; whether cybersecurity, electronic medical record or other sector-specific rules require review; and whether the proposed local use differs materially from the AI provider's intended use, documented purpose or classification.
The intake team does not need to resolve every legal question. Its role is to recognize when specialist review is necessary.
This is particularly important when a healthcare organization acts as a deployer rather than the statutory AI provider. The organization should obtain and understand relevant classification, regulatory and technical documentation from the provider, but the provider's classification does not resolve every local clinical-governance question. Conversely, a hospital should not casually assume statutory responsibilities that belong to the AI provider.
A sound intake and routing process should preserve these role distinctions.
Personal data should trigger early data-protection screening
Many healthcare AI proposals involve personal or sensitive information, either directly or through the outputs they generate.
Viet Nam's Law No. 91/2025/QH15 on Personal Data Protection and Decree No. 356/2025/NĐ-CP have both been effective since 1 January 2026 [4,5]. Decree No. 356 contains provisions specifically relevant to AI. Data generated through AI inference must receive personal-data protection where they can identify or help identify a particular individual. For automated personal-data processing, personal-data controllers and controller-processors must notify data subjects, explain the operating principles of the relevant algorithms and their potential effects on lawful rights and interests, and provide options enabling data subjects not to participate in the automated processing [5].
Intake therefore needs to establish early whether personal data are involved, but a checkbox stating “uses patient data” is not enough. The organization needs to understand where the data originate, which categories of data are involved, whether information leaves the healthcare organization's environment, where processing occurs, which third parties receive data, whether the vendor or AI provider uses the data for additional purposes such as service improvement or model development, whether AI outputs generate new information about identifiable individuals and what happens to data after the relevant relationship ends.
Detailed legal and privacy assessment may occur later. The purpose of intake is to make sure the need for that review becomes visible before the organization is operationally or contractually committed.
Data questions are not only privacy questions
An AI proposal may satisfy privacy requirements and still be unsuitable for clinical use because the available data are not fit for purpose. Intake should therefore distinguish data protection from data suitability.
What data does the system require? Are those data routinely available? Are they sufficiently complete? Are coding practices consistent? Does the organization have the interfaces needed to provide expected inputs? Could missingness alter system behavior? Does the proposed implementation rely on information recorded differently across departments or sites?
These questions matter because an AI system may have strong external evidence but behave differently when local inputs differ from those used in development or validation. Intake does not need to conduct full data validation, but it should recognize when a proposal requires deeper data-quality or data-lineage assessment before deployment.
Clinical evidence should be screened before procurement momentum builds
A vendor demonstration is not clinical evidence.
Intake should therefore ask what evidence supports the intended use. Is there external validation? Were relevant patients represented? What outcomes were assessed? Were important subgroups analyzed? Was the system evaluated prospectively or only retrospectively? Does the available evidence support the actual use being proposed, rather than merely a related application?
The purpose at intake is not to complete a full evidence appraisal. It is to determine whether formal evidence review is necessary and whether there is enough information to justify moving further into procurement, pilot planning or local validation.
A proposal with limited evidence does not always need to be rejected. It may be suitable for a tightly controlled evaluation or pilot. But uncertainty should remain visible and should influence what the organization permits next.
This prevents commercial or operational momentum from turning a poorly evaluated technology into a de facto approved system before its evidence has been properly examined.
The proposed workflow should be visible during intake
AI does not create risk independently of the workflow in which it is used. Intake should therefore include a simple description of what will change in practice. Who receives the output? What are they expected to do with it? Does AI create a new alert, change prioritization, remove an existing review step, require someone to verify generated content or create new escalation and documentation responsibilities?
The organization should also identify where additional work is likely to appear. AI may reduce workload for physicians while increasing it for nurses. A documentation assistant may save typing while creating correction work. A predictive model may reduce manual screening but create many more alerts. A patient-facing tool may reduce routine calls while generating more complex follow-up questions.
These issues do not necessarily require full human-factors assessment during intake. But a proposal that cannot explain how AI fits into actual work should not proceed directly to routine implementation.
Human oversight needs to be screened early
Organizations often hear that an AI system is safe because “a human remains in the loop.” That statement should start the questioning rather than end it.
Who is the human? What information will that person receive? How much time will they have to review the output? Can they independently verify it? What happens when they disagree? Can they override the AI? Are overrides visible and reviewed? What happens when no appropriately qualified person is available?
For a low-consequence administrative use, these questions may be simple. For clinical decision support, generative documentation, agentic AI or patient-facing systems, they may determine the depth and type of review required.
Intake should therefore screen whether proposed human oversight is operationally credible, not merely whether a human appears somewhere in a diagram or policy.
Autonomy and action authority should change the review pathway
AI that produces information is different from AI that can act. A system that summarizes a record for human review has different organizational implications from an AI agent that can send messages, access external tools, change schedules, initiate requests or trigger another system.
The intake process should therefore identify the system's action authority. What can it do without another person actively approving the action? Which systems can it access? Can it write into the clinical record? Can it communicate externally? Can it trigger another workflow? Can it initiate an order or request? Can it alter existing information?
The greater the system's authority and the more difficult an action is to reverse, the deeper the governance review should generally become.
This is also important because AI functionality can change rapidly. A product introduced as an informational assistant may later acquire agentic functions through a vendor update. An effective intake system therefore needs a mechanism for material new functionality to re-enter governance, rather than assuming that approval of the original product automatically covers everything the product may later become.
Third-party dependencies should become visible at intake
The AI product presented to a healthcare organization may represent only one layer in a longer technology chain. A vendor may depend on an external foundation model, cloud provider, API, subprocessor, cybersecurity service or data-hosting arrangement. Changes to those dependencies may alter performance, availability or data flows without the healthcare organization itself changing the local software.
CHAI's broader 2026 AI Governance Playbooks include Third Party Management as one of eight governance domains, and its AI Intake Playbook is positioned as a companion covering the initial intake and risk-assessment stages of third-party management [7,8].
The initial intake process does not require a complete technical inventory of every dependency before any discussion can proceed, but it should determine whether material external dependencies exist and whether the vendor or AI provider, as applicable, can describe them sufficiently for later due diligence.
If a vendor cannot explain where patient information is processed, what major external model supports the service or what happens when an upstream service materially changes, the organization has identified a governance issue before it becomes a contractual or patient-safety problem.
Intake should route the request to the right reviewers
The value of triage lies not in collecting information for its own sake, but in routing information to people who can act on it.
A proposed clinical decision-support system may require clinical leadership, quality and patient-safety review. A system processing personal data may require data-protection and data-governance assessment. Cloud or API dependencies may require cybersecurity and architecture review. Software that may meet medical-device requirements needs appropriate regulatory review. A patient-facing system may require clinical, communication, accessibility and patient-experience input. A system that substantially alters work may require operational or human-factors assessment.
Not every proposal requires every reviewer. That is the purpose of risk-proportionate governance.
Joint Commission's 2026 voluntary Responsible Use of AI in Healthcare certification provides a useful international organizational reference point. Its standards assess whether healthcare organizations have formal governance, an organization-wide AI policy, criteria for governed tools, stakeholder review and approval processes, data protections, risk and bias controls, lifecycle monitoring, safety-event reporting and staff education [9].
These standards do not create legal requirements for healthcare organizations in Viet Nam. They do, however, illustrate why AI proposals increasingly need to be connected to several organizational functions rather than left entirely to procurement or IT.
Use a small number of review pathways
Healthcare organizations can simplify triage by using a small number of organizational review pathways without copying the statutory low-, medium- and high-risk terminology.
A streamlined review might apply where AI has limited clinical consequence, does not materially change patient care, uses constrained data and has minimal action authority. An enhanced review may be appropriate where AI changes healthcare workflows, processes sensitive information, influences staff decisions or patient communication but remains meaningfully supervised. A comprehensive review may be warranted where AI materially influences diagnosis or treatment, has substantial action authority, directly affects vulnerable patients, creates difficult-to-reverse consequences, has important data or third-party dependencies, is intended for large-scale or multi-site deployment or raises significant regulatory questions.
These pathways should remain flexible. A single material concern may justify deeper review. An otherwise simple AI function that sends sensitive health information to a poorly understood external environment should not remain on a streamlined path merely because it does not directly make clinical decisions.
The pathways should determine depth of review, not predetermined outcomes. Comprehensive review does not mean a system should be rejected; it means the organization needs stronger evidence and broader scrutiny before deciding.
Missing information should be treated as a governance finding
One of the most useful functions of intake is revealing what the organization does not know. A vendor may not provide subgroup performance data. Development or validation populations may be poorly described. Data flows may remain unclear. The proposed workflow may still be vague. Nobody may know who will monitor the system after go-live, or the vendor may not have a clear process for communicating material updates.
These are not merely administrative inconveniences. They are governance findings.
CHAI's AI Intake Working Group reported that participating institutions often spent more time collecting missing information and following up on incomplete documentation than actually assessing the technology. Its draft framework is intended in part to make initial evidence more consistent and reusable [7].
An intake process should therefore allow an explicit status such as information insufficient to proceed to further review, rather than forcing reviewers into premature approval-or-rejection decisions. Uncertainty should remain visible until it has been resolved or consciously accepted under appropriate governance conditions.
Intake should end with a documented handoff
A proposal that proceeds beyond intake may move into evidence evaluation, data-protection assessment, cybersecurity review, vendor due diligence, regulatory review, local validation, pilot design, contracting or multidisciplinary approval. The intake record should identify what remains to be done and who owns the next step.
This prevents staff from assuming that because a proposal has “passed intake,” it has been approved for deployment. A useful decision record should capture the proposed use, assigned review pathway, important risks or uncertainties identified, evidence still required, organizational functions that must review the proposal and what has actually been authorized at the current stage.
Authorization may be deliberately limited. An organization may authorize vendor due diligence, not procurement; offline validation, not patient-facing use; or a controlled pilot, not routine deployment. Clear boundaries reduce the risk that governance decisions expand informally over time.
Procurement should receive governance information, not rediscover it
A well-designed intake process should improve procurement rather than duplicate it. By the time detailed commercial discussions begin, the organization should already understand the intended use, clinical or operational owner, major evidence requirements, preliminary data implications and key governance concerns.
Procurement can then use that information to guide vendor due diligence, contractual responsibilities, service levels, change notification, access to monitoring information, incident cooperation, termination rights and other relevant terms.
For public-sector healthcare organizations, internal AI intake does not replace applicable procurement, bidding, financial-management or public-asset requirements. It addresses a different question: whether and under what governance conditions the proposed AI should continue toward acquisition or deployment.
Clinical and governance requirements should inform procurement, rather than being discovered only after the purchasing process has already defined the solution.
Intake should also capture internally developed and embedded AI
A vendor questionnaire alone is not an organizational intake system. AI may be developed by an internal data team, created through a research collaboration, embedded within enterprise software or introduced through a software upgrade. Staff may also begin using external generative AI tools directly.
The same core governance questions should therefore apply regardless of where the capability originated.
The supporting evidence will differ. An internal development team may not have third-party assurance reports or a vendor contract, but it should still be able to explain intended use, development data, validation, version control, deployment boundaries, monitoring and ownership. A software update may not require a new procurement process, but a material new AI capability may change risk and should enter appropriate change-control and governance review.
Intake should follow the capability and proposed use, not merely the purchasing pathway.
Intake should connect to the AI inventory without becoming the inventory
AI intake and the AI inventory are closely related but have different purposes. Intake manages proposed or newly discovered AI uses before and during review. The inventory provides continuing visibility into systems that the organization has approved, deployed, is piloting, has restricted or has retired according to its governance model.
An intake register may therefore contain proposals that never become active AI systems: rejected proposals, duplicate requests, submissions returned for more evidence or projects abandoned before procurement.
When a proposal proceeds, relevant information should transfer into the AI inventory so that the system does not have to be rediscovered after go-live. This creates traceability across the lifecycle:
request → review → decision → implementation → monitoring → change → retirement
That traceability becomes increasingly important as the number and variety of AI systems grow.
Intake should connect with existing quality and patient-safety governance
Healthcare organizations in Viet Nam should avoid building an entirely separate bureaucracy around AI where existing governance structures can perform part of the work. Circular No. 19/2013/TT-BYT remains recorded as in force and provides the existing hospital quality-management framework, including organizational responsibilities, quality indicators and continuous improvement activities [6].
An AI intake process can therefore route clinically relevant systems into existing quality and patient-safety governance rather than assuming that every AI proposal belongs solely to IT. A deterioration model may need a clinical-safety owner. A documentation system may require record-quality review. An AI-enabled diagnostic pathway may require local validation. A patient-facing generative system may require communication and escalation controls.
The aim is not to create another committee for every AI product. It is to ensure that the right organizational capabilities become involved at the right point.
A practical Clinical AI Intake and Triage Framework
For healthcare organizations in Viet Nam, the approach proposed in this article can be summarized as:
identify the request → define the problem and intended use → collect minimum intake information → screen clinical, data, autonomy, regulatory and workflow consequences → assign a proportionate review pathway → identify required reviewers and evidence → decide whether information is sufficient to proceed → hand off to the next governance stage → capture the decision and maintain traceability
The first step makes proposed AI use visible. The second prevents a product from substituting for a clearly defined healthcare need. The third gathers enough information for triage without demanding a full assessment too early. The fourth identifies real-world consequences rather than relying on product labels. The fifth determines how deeply the proposal should be reviewed. The sixth connects the request with appropriate expertise. The seventh makes missing evidence explicit rather than hiding uncertainty. The eighth defines what happens next, while the final step preserves institutional memory.
This Clinical AI Intake and Triage Framework is proposed here as a practical organizational approach for healthcare AI governance. It is not the statutory AI risk-classification process under Vietnamese law, a regulatory conformity-assessment procedure, an official government framework or a validated certification or maturity model.
Nor is it a reproduction of CHAI's AI Intake Playbook. CHAI's October 2026 materials provide an important and timely international reference, particularly for vendor AI intake, but they remain a draft framework undergoing pilot testing. The broader approach proposed here extends the intake concept to the different ways AI may enter healthcare organizations in Viet Nam.
What healthcare organizations should avoid
The most obvious failure pattern is procurement first, governance later, but several others matter. Healthcare organizations should avoid allowing every department to invent its own AI approval process, treating IT approval as clinical approval, assuming a vendor's marketing or regulatory documentation proves suitability for local clinical use, treating “human in the loop” as sufficient evidence of meaningful oversight, or assuming that approval of a software platform automatically covers every future AI feature.
The opposite problem is an intake process so burdensome that staff bypass it. Good governance needs enough friction to identify meaningful risk, but not so much that responsible users are discouraged from requesting review.
A practical design is therefore a short common front door followed by deeper review only where the proposed use justifies it. This is consistent with the underlying principle of CHAI's intake work: common baseline information combined with risk-proportionate evidence and controls rather than imposing the same burden on every AI solution [7].
Intake needs governance ownership and service expectations
An intake form without ownership eventually becomes an inbox. Someone needs responsibility for ensuring that a submission is reviewed, routed and closed. In a large health system this may be an AI governance office or multidisciplinary governance function. In a smaller hospital or specialty organization, ownership may sit within an existing quality, clinical-governance, digital-health or executive structure.
The organization should also define reasonable expectations for what happens after submission. Who performs the initial screen? When is a proposal returned because information is incomplete? How are urgent questions handled? Who resolves disagreement about the assigned review pathway? How is the requester informed about the outcome and next steps?
This matters because governance delay can itself encourage shadow processes. If formal review appears opaque or indefinite, departments may start pilots outside the intended route. A useful intake function therefore needs to be credible, proportionate and usable, not simply rigorous.
The framework should evolve as the organization learns
No intake form will remain complete indefinitely. New AI capabilities will appear. Agentic systems will create different questions about tool access and action authority. Vendor architectures will change. Regulation will evolve. The organization will also learn from its own experience: some questions that once seemed essential may add little value, while incidents and difficult reviews may reveal missing fields.
CHAI itself is treating its October 2026 framework as a draft to be tested with healthcare delivery organizations and vendors, with pilot findings intended to shape later revisions [7]. Healthcare organizations should use a similar learning approach locally.
Which submissions repeatedly arrive incomplete? Which questions rarely change routing or decisions? Which risks are being discovered too late? Are reviewers receiving the information they need? Are relatively low-consequence proposals being over-reviewed? Are important uses bypassing the process?
A good intake system should therefore have its own improvement loop. Its quality is demonstrated not by leaving the form unchanged, but by learning how to ask better questions earlier.
What this means for healthcare organizations in Viet Nam
As AI adoption grows, one of the hardest governance problems may eventually become volume rather than any single technology. One AI system can be discussed in a committee meeting. Twenty systems arriving through different departments, vendors and software platforms require an operating process. Fifty systems require a reliable way to distinguish which proposals need intensive scrutiny and which can move through a lighter pathway without compromising safety.
Before procurement or deployment, healthcare organizations need enough information to understand what problem is being addressed, what AI will do, what data it will use, whose work and care it will affect, what evidence exists and what could happen if it fails. They also need a reliable way to identify which questions belong to clinical governance, quality and patient safety, data protection, cybersecurity, regulatory affairs, procurement or other functions.
The purpose is not to place an AI committee between every employee and every technology. It is to make sure that material AI use becomes visible early enough for the organization to govern it deliberately.
The practical transition is therefore from discovering AI during procurement → to identifying AI at entry → to triaging the proposed use → to routing the right evidence to the right reviewers → to making proportionate, traceable governance decisions before deployment.
A healthcare organization that can do this consistently has more than an approval process. It has a functioning front door for responsible healthcare AI.
Professional education notice
This article is intended for professional education and knowledge exchange. It does not constitute individualized legal, regulatory, clinical, procurement, cybersecurity, medical-device, data-protection, accreditation or quality-management advice.
The Clinical AI Intake and Triage Framework described in this article is a practical organizational governance approach. It is not the statutory risk-classification mechanism prescribed by Law No. 134/2025/QH15 or Decree No. 142/2026/NĐ-CP, a conformity-assessment procedure, an official Vietnamese government framework or a certification standard.
The terms streamlined review, enhanced review and comprehensive review are organizational review pathways proposed in this article and should not be confused with the statutory low-, medium- and high-risk classifications under Vietnamese AI law.
The applicability of AI regulation, personal-data protection, medical-device requirements, cybersecurity requirements, procurement rules and other sector-specific obligations depends on the characteristics, intended use, legal role of the relevant actors and deployment context of the particular system.
CHAI's AI Intake Playbook and associated controls are used as an international reference point. As of this review, the materials released on 1 October 2026 remain a draft framework entering pilot testing and should not be presented as a mandatory standard or Vietnamese regulatory requirement.
References
National Assembly of Viet Nam. Law No. 134/2025/QH15 on Artificial Intelligence. Adopted 10 December 2025; effective 1 March 2026.
Government of Viet Nam. Decree No. 142/2026/NĐ-CP Detailing a Number of Articles and Measures for Implementation of the Law on Artificial Intelligence. Issued 30 April 2026; effective 1 May 2026.
Prime Minister of Viet Nam. Decision No. 33/2026/QĐ-TTg Promulgating the List of High-Risk Artificial Intelligence Systems. Issued 30 June 2026; effective 15 August 2026.
National Assembly of Viet Nam. Law No. 91/2025/QH15 on Personal Data Protection. Adopted 26 June 2025; effective 1 January 2026.
Government of Viet Nam. Decree No. 356/2025/NĐ-CP Detailing a Number of Articles and Measures for Implementation of the Law on Personal Data Protection. Issued 31 December 2025; effective 1 January 2026.
Ministry of Health of Viet Nam. Circular No. 19/2013/TT-BYT Providing Guidance on Management of Quality of Medical Examination and Treatment Services in Hospitals. Issued 12 July 2013; effective 15 September 2013; currently recorded as in force.
Coalition for Health AI. AI Intake Playbook and AI Intake Controls and Evidence Workbook. Released as a draft framework on 1 October 2026; pilot phase underway.
Coalition for Health AI. AI Governance Playbooks. Released 27 May 2026.
Joint Commission. Responsible Use of AI in Healthcare Certification. Launched 1 June 2026.